CAR-Ts against other leukemia antigens such as CD-22 (B-cell ALL), CD7 (T-ALL/AML), CD5 (T-ALL) and CD123 (AML) are under various stages of development and clinical trials as is newer generations of CAR-T constructs aimed at increased specificity and efficacy with minimal toxicity. Here, CD22 is linked to acute lymphoblastic leukemia.